Jennifer Borrow

Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10

A. Oza, Y. Drew, R. Glasspool, 2022, British Journal of Cancer.

A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors

A. Oza, Y. Drew, G. Shapiro, 2017, Clinical Cancer Research.

Phase 1/2 study of oral rucaparib: Final phase 1 results.

G. Shapiro, P. LoRusso, H. Burris, 2014 .

A Phase I Dose-escalation and PK Study of continuous oral Rucaparib in Patients with advanced solid Tumors

Michael J. Flynn, Manish R. Patel, Geoffrey I. Shapiro, 2013 .

Opioid antagonists in the treatment of alcohol dependence

G. O’Leary, Jennifer Borrow, Roger D. Weiss, 2001, Current psychiatry reports.

A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors

A. Oza, Y. Drew, G. Shapiro, 2017, Clinical Cancer Research.